Surgical management of secondary hyperparathyroidism in uremia

被引:38
作者
Tominaga, Y [1 ]
机构
[1] Nagoya 2nd Red Cross Hosp, Dept Transplant Surg, Showa Ku, Nagoya, Aichi 466, Japan
关键词
secondary hyperparathyroidism; uremia; parathyroidectomy; parathyroid hyperplasia; recurrent hyperparathyroidism;
D O I
10.1097/00000441-199906000-00007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Advaneed secondary (renal) hyperparathyroidism (HPT) induced by uremia is one of the most serious complications for long-term hemodialysis patients. Parathyroidectomy (PTx) is indicated in patients with severely advanced renal HPT that is refractory to medical treatment, including calcitriol pulse therapy. The clinical effect of PTx is striking. However, skeletal deformity, vessel calcification, and remarkable reduction of bone content is irreversible. Therefore, it is important to perform PTx at the right time. Based on histopathological and pathophysiological investigations, nodular hyperplasia is monoclonal neoplasia with abnormal parathyroid hormone response to extracellular calcium and vitamin D. When parathyroid hyperplasia progresses to nodular hyperplasia, PTx should be required. Total PTx with forearm autograft is the preferred procedure for renal HPT, especially for patients who need to continue hemodialysis treatment after PTx. Removal of all parathyroid glands, including supernumerary glands, at the initial operation and proper choice of adequate parathyroid tissue for autograft are important to prevent persistent and recurrent HPT. In this series of 782 patients, the function of autografted parathyroid tissue is almost satisfactory and no retransplantation of cryopreserved parathyroid tissue was necessary; however, graft-dependent recurrent HPT was not negligible, In conclusion, total PTx with forearm autograft is very effective and adequate treatment for advanced renal HPT and parathyroid function can be controlled after PTx.
引用
收藏
页码:390 / 397
页数:8
相关论文
共 52 条
[1]  
AKERSTROM G, 1984, SURGERY, V95, P14
[2]  
Akizawa T, 1993, Curr Opin Nephrol Hypertens, V2, P558, DOI 10.1097/00041552-199307000-00006
[3]   INTRAVENOUS CALCITRIOL IN THE TREATMENT OF REFRACTORY OSTEITIS FIBROSA OF CHRONIC RENAL-FAILURE [J].
ANDRESS, DL ;
NORRIS, KC ;
COBURN, JW ;
SLATOPOLSKY, EA ;
SHERRARD, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (05) :274-279
[4]   MONOCLONALITY OF PARATHYROID TUMORS IN CHRONIC-RENAL-FAILURE AND IN PRIMARY PARATHYROID HYPERPLASIA [J].
ARNOLD, A ;
BROWN, MF ;
URENA, P ;
GAZ, RD ;
SARFATI, E ;
DRUEKE, TB .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (05) :2047-2053
[5]   ABNORMAL REGULATION OF PARATHYROID-HORMONE RELEASE BY CALCIUM IN SECONDARY HYPERPARATHYROIDISM DUE TO CHRONIC-RENAL-FAILURE [J].
BROWN, EM ;
WILSON, RE ;
EASTMAN, RC ;
PALLOTTA, J ;
MARYNICK, SP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1982, 54 (01) :172-179
[6]   LOSS OF THE RETINOBLASTOMA TUMOR-SUPPRESSOR GENE IN PARATHYROID CARCINOMA [J].
CRYNS, VL ;
THOR, A ;
XU, HJ ;
HU, SX ;
WIERMAN, ME ;
VICKERY, AL ;
BENEDICT, WF ;
ARNOLD, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (11) :757-761
[7]   PARATHYROID-HORMONE SUPPRESSION BY INTRAVENOUS 1,25-DIHYDROXYVITAMIN-D - A ROLE FOR INCREASED SENSITIVITY TO CALCIUM [J].
DELMEZ, JA ;
TINDIRA, C ;
GROOMS, P ;
DUSSO, A ;
WINDUS, DW ;
SLATOPOLSKY, E .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (04) :1349-1355
[8]   PROGRESSION OF UREMIC HYPERPARATHYROIDISM INVOLVES ALLELIC LOSS ON CHROMOSOME-11 [J].
FALCHETTI, A ;
BALE, AE ;
AMOROSI, A ;
BORDI, C ;
CICCHI, P ;
BANDINI, S ;
MARX, SJ ;
BRANDI, ML .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 76 (01) :139-144
[9]   Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism [J].
Farnebo, F ;
Teh, BT ;
Dotzenrath, C ;
Wassif, WS ;
Svensson, A ;
White, I ;
Betz, R ;
Goretzki, P ;
Sandelin, K ;
Farnebo, LO ;
Larsson, C .
HUMAN GENETICS, 1997, 99 (03) :342-349
[10]   1-ALPHA-HYDROXYVITAMIN-D-3 DERIVATIVES IN THE TREATMENT OF RENAL BONE-DISEASES - JUSTIFICATION AND OPTIMAL MODALITIES OF ADMINISTRATION [J].
FOURNIER, A ;
MORINIERE, P ;
OPRISIU, R ;
YVERNEAUHARDY, P ;
WESTEEL, PF ;
MAZOUZ, H ;
ELESPER, N ;
GHAZALI, A ;
BOUDAILLIEZ, B .
NEPHRON, 1995, 71 (03) :254-283